Dendreon (DNDN) Bear Now A Full-Fledged Bull
More News related to DNDN
- Dendreon Corp. (DNDN) Receives U.S. FDA Complete Response for PROVENGE CRPC Treatment
- Dendreon Receives FDA Acknowledgement of Complete Response
- Leerink Says Takeaway From Dendreon's (DNDN) Q3 Report is the Busy Preparations for Provenge
- Dendreon (DNDN) Reports Q3 Loss of $0.40, Misses by 19c
- Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
The bearish, turned Neutral, Brean Murray analyst on Dendreon (Nasdaq: DNDN) is now a full- fledged bull. Today, he upgraded the stock from Hold to Buy and set an aggressive $35 price target following yesterday's positive details on the PROVENGE IMPACT trial.
The firm said, "yesterday's Phase 3 IMPACT trial data fully delivered on what was promised in Dendreon's conference call two weeks ago. We believe that the p-values and confidence intervals, although close to being borderline, support approval because there appears to be no other way to explain the clear survival difference. Even the most worrisome adverse effect from the earlier pooled trial results (cerebrovascular accident CVA) was perfectly balanced in the IMPACT trial."
Notably, Brean Murray had a Sell rating on Dendreon into the April 14 preliminary positive IMPACT trial data. Following that data he moved to Neutral, now Buy with the details.
For more analyst ratings on Dendreon click here.
Get Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
Insiders' BlogMomentum Movers
Upgrades
Stocks Mentioned
-0.04Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
